BA3142 / BioAtla - LARVOL DELTA

Novel conditionally active tetravalent B7-H3 x CD3 T-cell engagers targeting solid tumors (AACR 2024) - "This DualCAB-TCE molecule, BA3142, was engineered to bind with high affinity to both recombinant B7-H3 and CD3 receptor/antigens under conditions that mimic the acidic tumor microenvironment, but with low affinity in alkaline physiological conditions...The CAB technology offers the opportunity to expand the number of targets suitable for drug development in a new class of DualCAB TCEs with superior safety margin and potency in the clinic.(1) Chang HW, Frey G, Liu H, Xing C, Steinman L, Boyle WJ, and Short, J.M. Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches. Proc Natl Acad Sci U S A 2021; 118."

IO biomarker • Oncology • Solid Tumor • CD276

BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) - "BioAtla...announced preclinical poster presentations at the upcoming 2024 American Association for Cancer Research (AACR) Annual Meeting....Five abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology. Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in a patient derived pancreatic cancer model. No clinical and histopathologic signs of toxicities in non-human primates with conditionally active tetravalent B7-H3 x CD3 T-cell engager (BA3142)."

Preclinical • Pancreatic Cancer • Solid Tumor